Tesofensine

Tesofensine is a triple monoamine reuptake inhibitor (serotonin, noradrenaline, dopamine) originally developed for neurodegenerative disease. Clinical trials showed pronounced appetite suppression and weight loss.

• Strong appetite suppression via monoamine pathways
• Sustained weight-loss effect in Phase II/III trials
• Complementary to GLP-1 stacks (different mechanism)

• Oral capsule/tablet form
• Typical: 250–500 mcg daily
• Long half-life (~9 days) — steady-state builds over 4–6 weeks
• Cycle rather than continuous long-term use in research protocols

• Elevated heart rate, insomnia, dry mouth, mood changes possible
• Avoid combining with SSRIs, MAOIs, or other monoaminergic drugs
• Not appropriate for individuals with cardiovascular or psychiatric conditions

Supplied as an oral capsule — no reconstitution required. Typical capsule: 500 mcg.

• Common research dosing: 250–500 mcg daily with gradual titration
• Duration: 8–24 weeks depending on study goals

CNS stimulant activity makes it less tolerable for sensitive populations. Side effects may include insomnia, jitteriness, elevated heart rate, and dry mouth.

Appetite Overdrive Stack:

• Retatrutide: 5–10 mg weekly (SubQ)
• Tesofensine: 250–500 mcg daily (oral)
• Duration: 8–12 weeks depending on tolerability

It's described the combination as covering both central and peripheral appetite suppression — 'food noise completely gone'. Not for those sensitive to stimulants; the overlap can be too strong and food intake sometimes drops too low.